Earnings Call · Q4 FY2021·2022-03-16

Q4 21EPS -78.95%·Rev n/aQ3 21EPS -84.62%·Rev n/aQ2 21EPS +28.57%·Rev n/aQ1 21EPS 0.00%·Rev n/a⚠ consensus missing

Eton Pharmaceuticals, Inc. ETON

David Krempa — Chief Executive Officer

Sean Brynjelsen — Chief Commercial Officer

Wilson Troutman — Chief Financial Officer

0.0%1d on move date−2.2% vs SPY3d+7.1%5d+10.2%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ETON calls or request research access.

More ETON calls Browse calls Request research access